Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.
Smith, Kenneth J., Mary Patricia Nowalk, Mahlon Raymund, and Richard K. Zimmerman. Cost-Effectiveness of Pneumococcal Conjugate Vaccination in Immunocompromised Adults. Vaccine. 2013; 31(37): 3950-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742552/